Loading...
•
Jun 30, 2020
Heron Therapeutics Q2 2020 Earnings Report
Reported financial results for Q2 2020 and highlighted recent corporate updates.
Key Takeaways
Heron Therapeutics reported net product sales of $22.7 million for the three months ended June 30, 2020, compared to $36.7 million for the same period in 2019. The net loss for the three months ended June 30, 2020 was $55.2 million, or $0.61 per share, compared to $50.2 million, or $0.63 per share, for the same period in 2019.
Received positive CHMP opinion for ZYNRELEF™ in the EU.
Received Complete Response Letter from the FDA regarding the NDA for HTX-011.
Initiated Phase 1b/2 Clinical Study of HTX-034 for the Treatment of Postoperative Pain.
Initiated Phase 2 Clinical Study of CINVANTI® for the Treatment of COVID-19.
Heron Therapeutics
Heron Therapeutics
Heron Therapeutics Revenue by Segment
Revenue by Segment
CINVANTI Revenue
CapyFin.comSUSTOL Revenue
CapyFin.com Forward Guidance
Heron anticipates a decrease in new diagnoses and chemotherapy patient starts because of the onging COVID-19 pandemic, the Company is maintaining its 2020 guidance for net product sales for the CINV franchise of $70 million to $80 million.